NeOnc Raises $5M via Preferred Stock with $1 Floor and 4.99% Cap
NTHI•NeOnc Technologies secured up to $5 million through Series A convertible preferred stock featuring redemption rights, a 4.99% ownership cap (expandable to 9.99%), and a $1.00 conversion floor. Proceeds will fund its glioblastoma-focused NEO100 and NEO212 programs as Phase 2 clinical updates approach.
1. New $5M Convertible Preferred Financing
NeOnc Technologies entered into a Securities Purchase Agreement with accredited investors to issue up to $5 million of Series A Convertible Preferred Stock. This financing aims to bolster the balance sheet as NeOnc advances its neuro-oncology pipeline.
2. Protective Ownership and Conversion Terms
The preferred shares include redemption rights, a 4.99% beneficial ownership cap per investor (with an option to increase to 9.99%), and a fixed $1.00 conversion floor to limit downward dilution risks typically seen in floating-rate convertibles.
3. Pipeline Advancement and Upcoming Milestones
Proceeds are earmarked for NEO100 and NEO212 programs targeting glioblastoma and other aggressive CNS cancers. Phase 2 clinical updates, viewed as critical inflection points, are expected soon and could drive increased institutional interest and partnerships.
4. Trading Volume Surge and Insider Buying
The financing news spurred NeOnc’s second-highest trading volume since listing. CEO Amir Heshmatpour purchased over $500,000 of stock recently, taking cumulative insider buys close to $1 million, signaling management confidence.
